Pharmaceutical Sector Expected to See Increased Investment in Innovative Antimicrobial and Antibacterial Therapies Over the Next 3-10 Years Due to Rising Antimicrobial Resistance and the Urgent Need for New Treatment Paradigms.
GSKJNJMRKPFERHHBY
Statements (2)
- Bullish
Pharmaceutical Companies Developing Novel Antibiotics Will Likely See Increased Investment Interest in the coming years Due To the abstract's focus on BV100, a new IV formulation of rifabutin targeting serious Acinetobacter baumannii infections, highlighting a growing need for effective treatments against resistant pathogens.
- Bullish
Pharmaceutical Companies Developing Novel Antimicrobial Agents Will Likely See Increased Investment In innovative drug pipelines over the next 5-10 years Due To the abstract's emphasis on the urgent need for new antimicrobial scaffolds to combat antimicrobial resistance (AMR)